Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DYV350
- Development stage
- Unknown
- Lead developer
- Dyve Biosciences
- Administration
- Topical, Transdermal
01
Overview
DYV350 is a biologic drug candidate developed by Dyve Biosciences. It is currently in Phase 1 clinical development. The drug is being investigated for its potential to induce adipolysis, which suggests it may be targeted at conditions involving excess adipose tissue or fat metabolism disorders. Dyve Biosciences specializes in developing novel small molecule and biologic drugs using proprietary topical delivery technology, enabling efficient transdermal administration and systemic or local effects. While the precise mechanism of action for DYV350 has not been disclosed, the company’s lead programs generally focus on modulating acidic microenvironments to treat immunological and oncological diseases.
Beyond the preview
Go deeper on DYV350.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DYV350.